(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.)
The rampant success of new prescription GLP-1 drugs has turned out to be both a tailwind and a huge risk for health tech’s emerging group of weight loss management companies.
Calibrate, which made its name as a place where people could go to get access to the drugs in the early days of approvals, is increasingly facing competition from companies like Noom and WeightWatchers — and even drugmaker Eli Lilly to be the place to go when seeking prescription weight loss care. To stay competitive, Calibrate and companies like it have to show evidence that their approaches go further than providing access to weight loss medications.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.